BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:22UA - US09075V1026 - ADR
84.6 EUR
+0.1 (+0.12%)
We assign a fundamental rating of 3 out of 10 to 22UA. 22UA was compared to 78 industry peers in the Biotechnology industry. While 22UA seems to be doing ok healthwise, there are quite some concerns on its profitability. 22UA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year 22UA has reported negative net income.
In the past year 22UA has reported a negative cash flow from operations.
Of the past 5 years 22UA 4 years were profitable.
Of the past 5 years 22UA 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -2.68%, 22UA is in the better half of the industry, outperforming 70.51% of the companies in the same industry.
22UA has a Return On Equity of -3.09%. This is in the better half of the industry: 22UA outperforms 75.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROIC | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 85.62%, 22UA is in the better half of the industry, outperforming 76.92% of the companies in the same industry.
In the last couple of years the Gross Margin of 22UA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for 22UA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
2. Health
2.1 Basic Checks
22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, 22UA has more shares outstanding
22UA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 22UA has a worse debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.24 indicates that 22UA is not in any danger for bankruptcy at the moment.
The Altman-Z score of 22UA (6.24) is better than 83.33% of its industry peers.
22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
22UA has a better Debt to Equity ratio (0.01) than 79.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.24 |
ROIC/WACCN/A
WACC7.23%
2.3 Liquidity
22UA has a Current Ratio of 7.12. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of 22UA (7.12) is better than 88.46% of its industry peers.
A Quick Ratio of 7.02 indicates that 22UA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.02, 22UA belongs to the best of the industry, outperforming 88.46% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 |
3. Growth
3.1 Past
22UA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -20.92%.
Looking at the last year, 22UA shows a small growth in Revenue. The Revenue has grown by 3.70% in the last year.
22UA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.73% yearly.
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
3.2 Future
The Earnings Per Share is expected to grow by 14.03% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.18% on average over the next years.
EPS Next Y-72.94%
EPS Next 2Y-16.12%
EPS Next 3Y-13.43%
EPS Next 5Y14.03%
Revenue Next Year-16.11%
Revenue Next 2Y-4.16%
Revenue Next 3Y-0.61%
Revenue Next 5Y2.18%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for 22UA. In the last year negative earnings were reported.
Also next year 22UA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
22UA's earnings are expected to decrease with -13.43% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-16.12%
EPS Next 3Y-13.43%
5. Dividend
5.1 Amount
22UA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FRA:22UA (11/24/2025, 5:27:31 PM)
84.6
+0.1 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners23.44%
Inst Owner ChangeN/A
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap20.34B
Revenue(TTM)3.15B
Net Income(TTM)-571.60M
Analysts80
Price Target121.21 (43.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.13%
Min EPS beat(2)21.85%
Max EPS beat(2)44.42%
EPS beat(4)4
Avg EPS beat(4)77.6%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)44.65%
EPS beat(12)9
Avg EPS beat(12)207.14%
EPS beat(16)12
Avg EPS beat(16)164.98%
Revenue beat(2)2
Avg Revenue beat(2)63.4%
Min Revenue beat(2)55.06%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)33.69%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)5
Avg Revenue beat(8)18.96%
Revenue beat(12)6
Avg Revenue beat(12)5.54%
Revenue beat(16)9
Avg Revenue beat(16)12.1%
PT rev (1m)2.29%
PT rev (3m)0.57%
EPS NQ rev (1m)89.1%
EPS NQ rev (3m)78.61%
EPS NY rev (1m)1.7%
EPS NY rev (3m)9.25%
Revenue NQ rev (1m)-14.11%
Revenue NQ rev (3m)-14.98%
Revenue NY rev (1m)1.98%
Revenue NY rev (3m)12.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 6.45 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.1 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.37
EYN/A
EPS(NY)-3.75
Fwd EYN/A
FCF(TTM)-4.55
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS13.11
BVpS76.84
TBVpS69.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.68% | ||
| ROE | -3.09% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.62% | ||
| FCFM | N/A |
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 202.92% | ||
| Cap/Sales | 24.68% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.12 | ||
| Quick Ratio | 7.02 | ||
| Altman-Z | 6.24 |
F-Score3
WACC7.23%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.81%
EPS Next Y-72.94%
EPS Next 2Y-16.12%
EPS Next 3Y-13.43%
EPS Next 5Y14.03%
Revenue 1Y (TTM)3.7%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%22.02%
Revenue Next Year-16.11%
Revenue Next 2Y-4.16%
Revenue Next 3Y-0.61%
Revenue Next 5Y2.18%
EBIT growth 1Y-6.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.41%
EBIT Next 3Y5.33%
EBIT Next 5Y19.79%
FCF growth 1Y-123.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.92%
OCF growth 3Y-38.43%
OCF growth 5YN/A
BIONTECH SE-ADR / 22UA.DE FAQ
What is the ChartMill fundamental rating of BIONTECH SE-ADR (22UA.DE) stock?
ChartMill assigns a fundamental rating of 3 / 10 to 22UA.DE.
Can you provide the valuation status for BIONTECH SE-ADR?
ChartMill assigns a valuation rating of 0 / 10 to BIONTECH SE-ADR (22UA.DE). This can be considered as Overvalued.
Can you provide the profitability details for BIONTECH SE-ADR?
BIONTECH SE-ADR (22UA.DE) has a profitability rating of 3 / 10.
How financially healthy is BIONTECH SE-ADR?
The financial health rating of BIONTECH SE-ADR (22UA.DE) is 6 / 10.
Can you provide the dividend sustainability for 22UA stock?
The dividend rating of BIONTECH SE-ADR (22UA.DE) is 0 / 10 and the dividend payout ratio is 0%.